Citations

Clear

249 citation(s) found for "St-Denis, L".

Identifying the most attractive umbilical position – an eye tracking- and survey-based investigation
Moellhoff, Nicholas , Staiger, Tim J., Ehrl, Denis, Kohler, Lukas H., Guertler, Anne, Giunta, Riccardo E., Cotofana, Sebastian, Frank, Konstantin, Ehrl, Denis , Giunta, Riccardo E. , Kohler, Lukas , Moellhoff, Nicholas , Staiger, Tim J., Guertler, Anne, Cotofana, Sebastian, Frank, Konstantin

Mayo Clinic

Journal of Plastic Surgery and Hand Surgery | December 22, 2021 | Volume: 56 | Issue: 6 | Pages: 369-375

10.1080/2000656x.2021.2017946 | PMID 34935586 Get It

Development of pemphigus vulgaris after the second dose of the mRNA‐1273 SARS‐Cov‐2 vaccine
Koutlas, Ioannis G. , Camara, Renee, Davis, Mark D.P. , Miller, Daniel D. , Davis, Mark Denis P., Argyris, Prokopios P.

Mayo Clinic

Oral Diseases | November 26, 2021 | Volume: 28 | Issue: S2 | Pages: 2612-2613

10.1111/odi.14089 | PMID 34825752 Get It

Prolonged Omacetaxine Treatment Alters Fitness and Proteostasis in Multiple Myeloma
Reiman, Lauren T. , Walker, Zachary J. , Steinmetz, Rachel N. , Ohlstrom, Denis , Mills, Taylor , Idler, Beau M. , Stevens, Brett M. , Pietras, Eric Martin , Sherbenou, Daniel W

Mayo Clinic

Blood | November 23, 2021 | Volume: 138 | Issue: Supplement 1 | Pages: 1604-1604

10.1182/blood-2021-151953 Get It

Abstract Background: Protein production and homeostasis are critical to life and death decisions of malignant plasma cells in multiple myeloma (MM). While protein homeostasis has been targeted effectively with proteasome inhibitors in this disease, inhibition of protein production has not been clinically tested. Protein translation inhibition represents an immediately available avenue, with the agent omacetaxine mepesuccinate (Oma). Recent in vivo and ex vivo work illustrates the broad sensitivity MM cells have to Oma, irrespective of proteasome inhibitor (PI) or immunomodulatory (IMiD) drug treatment exposure (Walker et al. Clinical Cancer Research, 2021). High levels of baseline protein translation, compared to other cells in the bone marrow, serves as a biomarker of high Oma sensitivity in MM patient samples. Based on this, we hypothesized that Oma treatment in MM may lead to eventual drug resistance through the downregulation of protein synthesis. To test this, we evaluated the effects of long-term Oma treatment on MM cells, by establishing resistance in two human MM cell lines and comparing them to their isogenic parental lines. Methods: Omacetaxine resistance was established by dose escalation in MM cell lines NCI-H929 and MM1S, with concentrations gradually increased over 80 weeks to 84 nM and 52 nM, respectively. Resistance was confirmed via CellTiter-Glo after 96 h incubations. Translation rates were measured by incorporation of OP-Puromycin. Flow cytometry was used for cell cycle analysis. Mass cytometry (CyTOF) was performed on a Fluidigm Helios system with a 35-marker panel. Cell morphology was examined by confocal microscopy using a Zeiss LSM780 spectral microscope with DAPI and Mitotracker stains. Cell line xenograft studies were performed using NSG mice engrafted via IV tail injection. Results: Resistant cell lines H929-R and MM1S-R displayed decreased cytotoxicity to Oma, with EC50 >100 nM after 96 h treatment, compared to parental line sensitivity of 24 nM for MM1S and 54 nM for H929 (Fig 1A and 1B). Next, we evaluated baseline translation rates for both parental and resistant lines. As hypothesized, H929 cells significantly downregulated translation after acquiring Oma resistance, but MM1S cells actually significantly upregulated protein synthesis (n = 3, p < 0.001 for both lines, Fig 1C). Interestingly, MM1S-R cells showed global phenotypic changes from the parental line based on UMAP analysis of CyTOF results, whereas H929-R appeared similar to its isogenic line (Fig 1D). The most altered protein was the transcription factor XBP1s, which was elevated in MM1S-R cells compared to parental (Fig 1E). An increased percentage of aneuploidy cells was observed in both resistant lines compared to the parental lines, indicating genomic pressure on both (Fig 1F). Consistent with this, confocal microscopy showed the emergence of multi-nucleated and pleomorphic cells in the Oma resistant lines compared to parental (Fig 1G). Finally, both resistant lines showed a surprising extended survival in an untreated MM NSG xenograft model. Mice engrafted with either H929-R or MM1S-R had a significant survival advantage over their parental cell lines (p = 0.0019, p = 0.0014, Fig 1G and 1H). Median survival was 119 days for H929-P and unreached for H929-R mice, MM1S was 47 and 68 days respectively. Conclusion: After prolonged exposure to Oma, cell lines H929 and MM1S displayed unique characteristics compared to their parental lines, including changes in protein translation rates, drug sensitivities, aneuploidy, and in vivo growth characteristics. Once resistant to Oma, H929 cells downregulated translation, similar to published patient sample data. Conversely, MM1S cells upregulated translation and displayed a more complex phenotypic shift, including an upregulation of XPB1s, an indication of increased unfolded protein response. Much like PIs, we believe Oma disrupts the delicate proteostasis intrinsic to MM cells, putting them on the defensive. Both Oma resistant cell lines exhibited a stressed cell state evident through their decline of in vivo fitness and an increase in poly-aneuploidy. Ongoing research with these cell lines will evaluate transcriptional changes, continuing to advance our understanding of Oma sensitivity and resistance in multiple myeloma. Figure 1 Figure 1. Disclosures No relevant conflicts of interest to declare.
Reliability of 3‐dimensional surface imaging of the face using a whole‐body surface scanner
Xu, Ya , Frank, Konstantin , Kohler, Lukas , Ehrl, Denis , Alfertshofer, Michael , Giunta, Riccardo Enzo , Moellhoff, Nicholas , Cotofana, Sebastian , Koban, Konstantin Christoph , Giunta, Riccardo E. , Cotofana, Sebastian , Alfertshofer, Michael , Giunta, Riccardo Enzo , Moellhoff, Nicholas

Mayo Clinic

Journal of Cosmetic Dermatology | November 3, 2021 | Volume: 21 | Issue: 4 | Pages: 1464-1470

10.1111/jocd.14555 | PMID 34731521 Get It

AbstractObjectiveTo the knowledge of the authors, no data about the reproducibility and accuracy of 3‐dimensional surface imaging of the face using a whole‐body scanner are available. Thus, the objective of this investigation was to assess the reproducibility of facial scans acquired using a whole‐body imaging device.Material and MethodsThis investigation investigated 220 3‐D scans of a total of 22 healthy volunteers (with a mean age of 29.36 years). Two consecutive 3‐D images using a Vectra WB360 of the volunteers were obtained utilizing a whole‐body imaging device. Predefined distances in the face were performed in each scan and compared. Furthermore, surface deviation between two consecutively captured scans was assessed.ResultsThe distance with the smallest statistical significance was found to be at the nose with p = 0.998, while the biggest statistical significance was found in the midface with p = 0.658. The area with the biggest surface deviation between the superimposed scans was the neck with a root mean square (RMS) of 1.62 ± 1.71, and the area with the smallest surface deviation was the forehead with a RMS of 0.17 ± 0.05.ConclusionThe whole‐body imaging device investigated in this study can be utilized to capture the face and provides enough accuracy to compare scans. Even though not directly investigated, it can be hypothesized that the error caused by repositioning the patient between a baseline and a follow‐up scan will not be too big to consider measurements performed with the whole‐body imaging device as impractical.
Predictors of Left Ventricular Outflow Tract Obstruction After Transcatheter Mitral Valve Replacement in Severe Mitral Annular Calcification: An Analysis of the Transcatheter Mitral Valve Replacement in Mitral Annular Calcification Global Registry
Sabbagh, Abdallah El , Al‐Hijji, Mohammed , Wang, Dee Dee , Eleid, Mackram F. , Ureña, Marina , Himbert, Dominique , Chakravarty, Tarun , Fang, Hao , Zahr, Firas , Dvir, Danny , Sardar, Muhammad , Cheema, Asim N. , Alnasser, Sami , Iyer, Vijay , Kaddissi, Georges, Webb, John G. , Makkar, Raj , Vahanian, Alec , Rihal, Charanjit S. , Eleid, Mackram F , Nejjari, Mohammed , Dvir, Danny , Rihal, Charanjit, Guerrero, Mayra E , Al-Hijji, Mohammed A , Wang, Dee Dee , Holzhey, David Michael , Pershad, Ashish , Nejjari, Mohammed , O’Neill, William W. , Rihal, Charanjit S. , Guerrero, Mayra

Mayo Clinic

Circulation: Cardiovascular Interventions | October 19, 2021 | Volume: 14 | Issue: 10 | Pages: No page available

10.1161/circinterventions.121.010854 | PMID 34665654 Get It

Background: Several studies have evaluated preprocedural imaging predictors of left ventricular outflow tract obstruction (LVOTO) after transcatheter mitral valve replacement. The patient cohorts in these studies were heterogeneous and included patients with transcatheter mitral valve replacement in failed bioprostheses, annuloplasty rings, and severe mitral annular calcification (MAC). The goal of this study was to evaluate predictors of LVOTO specific to patients undergoing valve-in-MAC. Methods: This study included patients with severe MAC who underwent valve-in-MAC and had optimal quality preprocedural multidetector row computed tomography scans eligible for retrospective analysis. Baseline demographic, echocardiographic, and procedural data on these patients were collected. multidetector row computed tomography parameters were analyzed for association with LVOTO, defined as increase in mean LVOT gradient by ≥10 mm Hg with accompanying hemodynamic instability. Results: Seventy-one patients with optimal preprocedural computed tomography scans were included in this study (mean age, 72.5±13.5 years), 9 of which developed LVOTO (all female). Baseline mean LVOT area, neo-LVOT area (145.3 versus 270.9 mm 2 ; P =0.006), indexed neo-LVOT area (90.1 versus 157.4; P =0.05), and virtual transcatheter heart valve to septum distance (3.1 versus 6.9 mm; P =0.002) were lower in the LVOTO group. Expected % LVOT area reduction was higher in the latter group (58.3 versus 42.7%; P =0.008). In the univariable analysis, the baseline mean LVOT area, neo-LVOT area, indexed neo-LVOT area, and valve to septum distance were all significantly associated with LVOTO. Conclusions: The systolic mean LVOT area, neo-LVOT area, indexed neo-LVOT, expected percentage LVOT area reduction, and the valve to septum distance were associated with LVOTO after valve-in-MAC.
­TREM2-H157Y Increases Soluble TREM2 Production and Reduces Amyloid Pathology
Qiao, Wenhui , Chen, Yixing , Martens, Yuka A. , Li, Fuyao , Aishe, Kurti I., Dacquel, Maxwell V., Fryer, John Denis , Chen, Kai , Li, Fuyao , Liu, Chia‐Chen , Knight, Joshua A. , Chen, Kai , Shue, Francis , Zhao, Na , Bu, Guojun

Mayo Clinic

No container title available | October 13, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-960300/v1 Get It

Abstract Background: The p.H157Y variant of TREM2 (Triggering Receptor Expressed on Myeloid Cells 2) has been reported to increase Alzheimer’s disease (AD) risk. This mutation in the extracellular domain of TREM2 localizes at the cleavage site and was shown to enhance shedding and impair phagocytosis in vitro by ectopic expression of TREM2-H157Y in HEK293 cells. However, the physiological and AD-related outcomes of TREM2 H157Y mutation in vivo remain unknown.Methods: We generated a novel Trem2 H157Y knock-in mouse model through CRISPR-Cas9 technology and investigated how Trem2 H157Y mutation impacts TREM2 proteolytic processing, synaptic function, and AD-related amyloid pathology by conducting biochemical assays, immunofluorescent staining, hippocampal electrophysiology, and in vivo micro-dialysis in awake, free-moving animals.Results: Consistent with previous in vitro findings, TREM2-H157Y increases the amount of soluble TREM2 (sTREM2) in the cortex and serum of mutant mice compared to the wild type controls. Interestingly, the Trem2 H157Y variant enhances synaptic plasticity without affecting microglial density and morphology. In the presence of amyloid pathology, TREM2-H157Y surprisingly accelerates Aβ clearance and reduces amyloid burden and microgliosis. Conclusion: Taken together, our findings support a beneficial effect of the Trem2 H157Y mutation in synaptic function and in mitigating amyloid pathology. Considering the genetic association of TREM2 p.H157Y with AD, we speculate TREM2-H157Y might increase AD risk through an amyloid-independent pathway, as such its effects on tauopathy and neurodegeneration merit further investigation.
APOE3 -Jacksonville (V236E) variant reduces self-aggregation and risk of dementia
Liu, Chia‐Chen , Murray, Melissa E. , Li, Xia , Zhao, Na , Wang, Na , Shue, Francis , Martens, Yuka A. , Li, Yonghe , Raulin, Ana‐Caroline , Rosenberg, Cassandra L. , Doss, Sydney V. , Wren, Melissa C. , Jia, Lin , Ren, Yingxue , Ikezu, Tadafumi C. , Lü, Wenyan, Trottier, Zachary A. , Chen, Yixing , Linares, Cynthia , Wang, Xue , Kurti, Aishe, Asmann, Yan W. , Vemuri, Prashanthi , Kantarci, Kejal , Lowe, Val J. , Jack, Clifford R. , Parisi, Joseph E., Ferman, Tanis J. , Graff‐Radford, Neill R. , Petersen, Ronald C. , Younkin, Steven G. , Fryer, John Denis , Frieden, Carl , Ross, Owen A. , Bu, Guojun , Shue, Francis , Atagi, Yuka , Raulin, Ana-Caroline , Doss, Sydney V , Zhao, Jing , Wren, Melissa C , Ikezu, Tadafumi C , Caulfield, Thomas R , Trottier, Zachary A , Wszolek, Z.K. , Smith, Glenn E. , Vemuri, Prashanthi , Jack, Clifford R , Ferman, Tanis J , Boeve, Brad , Petersen, Ronald C , Younkin, Steven , Frieden, Carl , Dickson, Dennis W , Ross, Owen A , Bu, Guojun , Liu, Chia-Chen , Kantarci, Kejal , Murray, Melissa E , Zhao, Na , Chen, Yixing , Heckman, Michael G. , Zhao, Jing , Fu, Yuan , Caulfield, Thomas R. , Knight, Joshua A. , Wszołek, Zbigniew K. , Knopman, David S. , Boeve, Bradley F. , Wang, Hu , Han, Xianlin , Dickson, Dennis W.

Mayo Clinic

Science Translational Medicine | September 29, 2021 | Volume: 13 | Issue: 613 | Pages: No page available

10.1126/scitranslmed.abc9375 | PMID 34586832 Get It

A rare APOE variant APOE3 -Jac reduces self-aggregation and promotes healthy brain aging.
Natural History and Progression of Transthyretin Amyloid Cardiomyopathy: Insights from ATTR-ACT
Nativi-Nicolau, José , Gundapaneni, Balarama, Keohane, Denis, Sultan, Marla B. , Grogan, Martha , Judge, Daniel P. , Hoffman, James E.

Mayo Clinic

ESC Heart Failure | August 25, 2021 | Volume: 8 | Issue: 5 | Pages: 3875-3884

10.1002/ehf2.13541 | PMID 34432383 Get It

Abstract Aims Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive, fatal disorder that remains underdiagnosed. The Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) was the first large clinical trial to include both wild-type (ATTRwt) and hereditary (ATTRv) patients. A description of the natural history of ATTR-CM, utilizing data from placebo-treated patients in ATTR-ACT, will provide a greater understanding of presentation and progression of ATTR-CM and may aid in disease awareness, earlier diagnosis and treatment monitoring. Methods and results Changes in clinical endpoints (mortality, cardiovascular [CV]-related hospitalizations, 6-min walk test [6MWT] distance and Kansas City Cardiomyopathy Questionnaire Overall Summary [KCCQ-OS] score) from baseline to Month 30 in the 177 patients (134 ATTRwt, 43 ATTRv) who received placebo in ATTR-ACT were assessed. ATTRwt patients tended to have less severe disease at baseline. Over the duration of ATTR-ACT, there were 76 (42.9%) all-cause deaths, and 107 (60.5%) patients had a CV-related hospitalization. There was a lower proportion of all-cause deaths in ATTRwt (49, 36.6%) than ATTRv (27, 62.8%). There was a similar, steady decline in mean (SD) 6MWT distance from baseline to Month 30 in ATTRwt (93.9 [93.7] m) and ATTRv (89.1 [107.2] m) patients. The decline in mean (SD) KCCQ-OS score was less severe in ATTRwt (13.8 [20.7]) than ATTRv (21.0 [26.4]) patients. Conclusions Patients with ATTR-CM experience a severe, progressive disease. In ATTR-ACT, placebo-treated patients with ATTRv, compared with ATTRwt, had more severe disease at baseline, and their disease progressed more rapidly as shown by mortality, hospitalizations and quality of life over time.
The Layered Anatomy of the Nose: An Ultrasound-Based Investigation
Alfertshofer, Michael , Frank, Konstantin , Ehrl, Denis , Freytag, David L., Beleznay, Katie, Swift, Arthur, Cotofana, Sebastian , Velthuis, Peter J. , Alfertshofer, Michael , Cotofana, Sebastian , Frank, Konstantin , Moellhoff, Nicholas , Gotkin, Robert H. , Mardini, Samir

Mayo Clinic

Aesthetic Surgery Journal | August 7, 2021 | Volume: 42 | Issue: 4 | Pages: 349-357

10.1093/asj/sjab310 | PMID 34363459 Get It

AbstractBackgroundAn increasing number of soft tissue filler procedures in the nasal region has been reported. Concomitant with demand, the number of complications has risen due to the difficulty in administering filler in a region where soft tissue layering is complex.ObjectivesThe authors sought to describe the layered soft tissue arrangement of the nose as it relates to the underlying arterial vasculature and to define safer zones for nasal filler enhancement.MethodsA total of 60 (28 males and 32 females) study participants were investigated with respect to their layered anatomy in the midline of the nose utilizing ultrasound imaging. The presence and extent of the layered arrangement was examined as well as the depth of the arterial vasculature.ResultsIn the mid-nasal dorsum, a 5-layer arrangement was observed in 100% (n = 60) of all investigated cases, whereas it was found to be absent in the nasal radix and tip. The 5-layer arrangement showed an average extent of 26.7% to 67.5% in relation to nasal length. The nasal arteries coursed superficially in 91.7% of all cases in the nasal radix, in 80% in the mid-nasal dorsum, and in 98.3% in the nasal tip.ConclusionsSoft tissue filler administration in the nose carries the highest risk for irreversible vision loss compared with any other facial region. The safety of soft tissue filler rhinoplasty procedures is enhanced by knowledge of the layered anatomy of the nose, the location and depth of the major nasal vasculature, and employment of maneuvers to decrease the risk of blindness.
A time series analysis of immune checkpoint inhibitor use in the United States Medicare population: 2014–2019
Puri, Pranav , Cortese, Denis A., Baliga, Sujith , Cortese, Denis, Puri, P

Mayo Clinic

Journal of Dermatological Treatment | July 27, 2021 | Volume: 33 | Issue: 4 | Pages: 2004-2007

10.1080/09546634.2021.1962002 | PMID 34314297 Get It